Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Italy ETF (EWI) vs Eli Lilly And Co (LLY) Price & Performance

Ishares Msci Italy ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Italy ETF vs Eli Lilly And Co — how do they compare? Ishares Msci Italy ETF trades at $60.54, while Eli Lilly And Co trades at $1,173.6 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals.

EWILLY
Sector
Broad Market / FactorHealth
52-Week High
$61.14$1.24K
52-Week Low
$47.75$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Italy ETF

The iShares MSCI Italy ETF (EWI) trades at $60.555, showing minimal daily movement with a slight 0.12% decline. Technical indicators present a mixed picture with an overall bullish signal from moving averages but neutral oscillators, while the stock recently hit a 52-week high according to Zacks Investment Research (June 10, 2026). The fund offers exposure to Italian equities amid a complex macroeconomic environment characterized by ECB rate hikes and energy price volatility.

EWI provides targeted exposure to Italy's market recovery narrative but faces significant stagflationary risks with projected 0.5% GDP growth and inflationary pressures from Middle East conflicts. The investment case balances improving industrial data against substantial macroeconomic headwinds, creating a high-risk, potentially high-reward scenario for investors seeking European diversification.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Italy ETF

EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.

Read more on EWI

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY